ACE-031 Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research
ACE-031 is a recombinant fusion protein developed by Acceleron Pharma that acts as a circulating molecular trap, capturing myostatin and other muscle-inhibitory proteins in the TGF-beta superfamily before they can reach muscle tissue. It reached Phase 2 clinical trials for Duchenne muscular dystrophy, where a single dose in healthy volunteers produced a 3.3% lean body mass increase and a 5.1% thigh muscle volume increase within 29 days - among the most striking acute muscle pharmacology findings in any human study. This guide covers ACE-031's mechanism, what the human and preclinical research shows, dosing context from clinical trial records, its safety profile, and its current regulatory status.
